Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853723 · ClinicalTrials.gov registry record · Phase 2
Comparison Study of PTHrP and PTH to Treat Osteoporosis
A Phase 2 study of Osteoporosis, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT00853723: Completed Phase 2 study of Osteoporosis, sponsored by University of Pittsburgh.
NCT00853723 is a Phase 2 study of Osteoporosis that has completed, run by University of Pittsburgh. The registered enrollment target is 105 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00853723, a Phase 2 study of Osteoporosis, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a three month comparison trial of standard dose parathyroid hormone (PTH) (1-34) and two different doses of Parathyroid Hormone-related Protein (PTHrP) (1-36). The investigators want to to demonstrate that daily subcutaneous injection of PTHrP (1-36) in postmenopausal women with osteoporosis stimulates bone formation to the same or greater degree than PTH (1-34) but with less bone resorption.
Conditions Studied
Interventions
- DRUG Parathyroid hormone related protein (1-36)
- DRUG Parathyroid hormone related protein(1-36)
- DRUG Parathyroid hormone (1-34)
Study Locations (1)
Pennsylvania
- UPMC Clinical & Translational Research Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT00853723 record still lists
NCT00853723 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 3 interventions - of which Parathyroid hormone related protein (1-36) is the first listed.
NCT00853723 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00853723 about?
NCT00853723 is a clinical study titled "Comparison Study of PTHrP and PTH to Treat Osteoporosis". This is a three month comparison trial of standard dose parathyroid hormone (PTH) (1-34) and two different doses of Parathyroid Hormone-related Protein (PTHrP) (1-36). The investigators want to to demonstrate that daily subcutaneous injection of PTHrP (1-36) in postmenopausal women with osteoporosis...
What is the current status of trial NCT00853723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2009-05. Estimated completion is 2012-06.
What conditions does trial NCT00853723 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT00853723?
The interventions under investigation include: Parathyroid hormone related protein (1-36) (DRUG), Parathyroid hormone related protein(1-36) (DRUG), Parathyroid hormone (1-34) (DRUG).
Who is sponsoring clinical trial NCT00853723?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00853723 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00853723's enrollment target sits among peer trials
105 37th of 84 higher than 48 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
RECRUITING · Phase 2
-
Calcium and Bone Mass in Young Females
COMPLETED · Phase 2
-
Hormone Replacement Therapy to Treat Turner Syndrome
COMPLETED · Phase 2
-
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
COMPLETED · Phase 2
-
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 2
-
Adding Phosphorus to Osteoporosis Drug Treatment
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia